Black Diamond Therapeutics Appoints Elizabeth Montgomery as Chief People Officer
February 22, 2022 08:00 ET
|
Black Diamond Therapeutics, Inc
CAMBRIDGE, Mass. and NEW YORK, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of...
Black Diamond Therapeutics Announces FDA Allowance of IND Application for BDTX-1535, A MasterKey Inhibitor of EGFR for the Treatment of Gliobastoma and Non-Small Cell Lung Cancer
January 11, 2022 07:00 ET
|
Black Diamond Therapeutics, Inc
CAMBRIDGE, Mass. and NEW YORK, Jan. 11, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of...
Black Diamond Therapeutics Announces Strategic Priorities and Expected Milestones for 2022
January 10, 2022 07:00 ET
|
Black Diamond Therapeutics, Inc
Company announces IND submission for BDTX-1535 for the treatment of GBM and NSCLC including those with CNS tumors;Company to enroll additional patients into MasterKey-01 Phase 1 safety expansion...
Black Diamond Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
January 05, 2022 08:00 ET
|
Black Diamond Therapeutics, Inc
CAMBRIDGE, Mass. and NEW YORK, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of...
Black Diamond Therapeutics to Present at Upcoming Investor Conferences
November 08, 2021 16:05 ET
|
Black Diamond Therapeutics, Inc
CAMBRIDGE, Mass. and NEW YORK, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of...
Black Diamond Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update
November 08, 2021 07:45 ET
|
Black Diamond Therapeutics, Inc
Black Diamond continues preparation for initiation of the Phase 2 portion of MasterKey-01 study of BDTX-189 this yearPre-clinical data from BDTX-1535, BRAF, and FGFR programs presented at...
Black Diamond Therapeutics Presents Preclinical Data on BDTX-1535, BRAF, and FGFR Programs at the 33rd AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 08, 2021 16:05 ET
|
Black Diamond Therapeutics, Inc
CAMBRIDGE, Mass. and NEW YORK, Oct. 08, 2021 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of...
Black Diamond Therapeutics to Present Pre-Clinical Data on BDTX-1535, BRAF, and FGFR Programs at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
September 30, 2021 16:35 ET
|
Black Diamond Therapeutics, Inc
CAMBRIDGE, Mass. and NEW YORK, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of...
Black Diamond Therapeutics to Present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference
September 21, 2021 16:05 ET
|
Black Diamond Therapeutics, Inc
CAMBRIDGE, Mass. and NEW YORK, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of...
Black Diamond Therapeutics and OpenEye Scientific Announce Collaboration to Expand MAP Drug Discovery Platform
September 21, 2021 07:45 ET
|
Black Diamond Therapeutics, Inc
Strategic partnership between Black Diamond and OpenEye aims to accelerate drug discovery efforts through cloud-based molecular dynamics technology CAMBRIDGE, Mass. and SANTA FE, N.M., Sept. 21,...